Tuesday, 26 May 2020: RCSI University of Medicine and Health Sciences and LEO Pharma have partnered to better understand the role of a blood clotting protein in the spread of breast cancer.
Cancer patients have a high risk of developing spontaneous blood clots, with up to 20% of cancer patients hospitalised with life-threating complications. As a result, clot formation is the second leading cause of death for all cancer patients.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
